CSPC PHARMA(01093): CSPC and RADIANCE BIOPHARMA reached an exclusive licensing agreement for SYS6005.

CSPC PHARMA (01093) announced that its subsidiary CSPC PHARMA Jiushi Biopharmaceutical Co., Ltd. (Jiushi) has entered into an exclusive licensing agreement with Radiance Biopharma, Inc. (Radiance Biopharma) for the development and commercialization of the group's recombinant anti-human receptor tyrosine kinase-like orphan receptor 1 (ROR1) antibody-drug conjugate SYS6005 (the product) in the United States, European Union, United Kingdom, Switzerland, Norway, Iceland, Liechtenstein, Albania, Montenegro, North Macedonia, Serbia, Australia, and Canada (the region). Under the terms of the agreement, Jiushi has agreed to grant Radiance Biopharma the exclusive right to develop and commercialize the product in the region. Jiushi will receive an upfront payment of $15 million and is eligible to receive up to $150 million in potential development and regulatory milestone payments, up to $1.075 billion in potential sales milestone payments, and tiered sales royalties based on the product's annual net sales in the region.